Evidence map›Paper›PMID 40978755›Full record

ArticleFrontiers in medicine2025

Global and Chinese trends in acute myeloid leukemia burden (1990-2021): a comprehensive analysis based on the GBD study.

Xiaojing Lu, Xin Peng, Yunxiang Zhang, Hongming Zhu, Yu Zheng, Yue Sun, Heyu Ji, Junmin Li, Haijiao Jin, Xiaoyang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Leukemia epidemiology in China: Burden, trends, and determinants in the 21st century.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaojing Lu *Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xin Peng *Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yunxiang ZhangShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hongming ZhuShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu ZhengShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yue SunDepartment of Medical Affairs, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Heyu JiDepartment of Medical Affairs, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Junmin LiShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Haijiao JinDepartment of Nephrology, Ren Ji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoyang Li *Department of Medical Affairs, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute myeloid leukemia (AML) poses a significant global health burden. This study evaluates long-term trends in AML burden from 1990 to 2021, focusing on global and Chinese patterns using Global Burden of Disease (GBD) data. Methods: We extracted AML-related mortality, incidence, prevalence, and disability-adjusted life years (DALYs) from the GBD 1990-2021 dataset. Age-standardized rates (ASRs) were analyzed using Joinpoint regression to calculate annual percentage change (APC) and average APC (AAPC). Contributions of smoking, high body mass index (BMI), and occupational exposures were also evaluated. Results: Globally, AML deaths rose by 73.8%, with a 17.45% increase in ASMR. Conversely, China's ASMR declined by 14.76%. DALYs showed a global AAPC of -0.83%, with a sharper decline in China (-2.40%). Males and older adults (>65 years) bore a disproportionate burden. Smoking remained the top risk factor, while high BMI showed the fastest growth in attributable burden. Conclusion: While AML's absolute burden is increasing worldwide, age-adjusted metrics are stabilizing or declining in China, likely due to healthcare improvements. Targeted prevention, risk control, and geriatric-oriented AML strategies are urgently needed.

Indexed as

acute myeloid leukemiaChinaDALYsepidemiologyGlobal Burden of Diseasemortalityrisk factors

Identifiers

PMID40978755
PMCPMC12446328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.